More on CCCC
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $3.87 |
|
|||
| Open | $3.88 | ||||
| 52 Wk High | $0.30 | ||||
| 52 Wk Low | $0.30 | ||||
| Day High | $4.25 | ||||
| Day Low | $3.84 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 1,841,734 | ||||
- Form 8-K C4 Therapeutics, Inc. For: Jun 11
- C4 Therapeutics reports 53% response rate in myeloma drug trial
- C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pret
- Form 4 C4 Therapeutics, Inc. For: Jun 01 Filed by: Anderson Kenneth Carl
- Form 144 C4 Therapeutics, Inc. Filed by: Mossler Mark
- C4 Therapeutics to Participate in Upcoming Conferences
- Form SCHEDULE 13G C4 Therapeutics, Inc. Filed by: Squadron Capital Management LLC
- C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Form SCHEDULE 13G/A C4 Therapeutics, Inc. Filed by: Point72 Asset Management, L.P.
- Form 8-K C4 Therapeutics, Inc. For: May 15
Entities mentioned with CCCC
- FDA | View Related Stories »
- 13G | View Related Stories »
- Earnings | View Related Stories »
- JPMorgan | View Related Stories »
- Jefferies & Co | View Related Stories »
- IPO | View Related Stories »
- UBS | View Related Stories »
- Cowen & Co | View Related Stories »
- Show More...
